200,000+ products from a single source!

sales@angenechem.com

Home > Amines > 113806-05-6

113806-05-6

113806-05-6 | Dibenz[b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino)propylidene]-6,11-dihydro-, (11Z)-

CAS No: 113806-05-6 Catalog No: AG0009QY MDL No:MFCD00865645

Product Description

Catalog Number:
AG0009QY
Chemical Name:
Dibenz[b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino)propylidene]-6,11-dihydro-, (11Z)-
CAS Number:
113806-05-6
Molecular Formula:
C21H23NO3
Molecular Weight:
337.4122
MDL Number:
MFCD00865645
IUPAC Name:
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid
InChI:
InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
InChI Key:
JBIMVDZLSHOPLA-LSCVHKIXSA-N
SMILES:
CN(CC/C=C/1\c2cc(ccc2OCc2c1cccc2)CC(=O)O)C
UNII:
D27V6190PM

Properties

Complexity:
488  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1  
Exact Mass:
337.168g/mol
Formal Charge:
0
Heavy Atom Count:
25  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
337.419g/mol
Monoisotopic Mass:
337.168g/mol
Rotatable Bond Count:
5  
Topological Polar Surface Area:
49.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.5  

Literature

Title Journal
Identification of old drugs as potential inhibitors of HIV-1 integrase - human LEDGF/p75 interaction via molecular docking. Journal of molecular modeling 20121201
Advantages of histamine H4 receptor antagonist usage with H1 receptor antagonist for the treatment of murine allergic contact dermatitis. Experimental dermatology 20120901
[A 10-week safety and efficacy evaluation of olopatadine, 0.2% instilled twice-daily in patients with allergic conjunctivitis in Japan]. Nippon Ganka Gakkai zasshi 20120901
The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice. Allergy 20120801
Stereoselective syntheses of the antihistaminic drug olopatadine and its E-isomer. The Journal of organic chemistry 20120720
Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clinical therapeutics 20120601
Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers. Archives of dermatological research 20120501
The effect of antihistamines on seizures induced by increasing-current electroshocks: ketotifen, but not olopatadine, promotes the seizures in infant rats. Biological & pharmaceutical bulletin 20120101
Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis. Expert opinion on drug metabolism & toxicology 20111201
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology 20111201
Thermal angiooedema induced by hot water. Acta dermato-venereologica 20110501
Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis. American journal of ophthalmology 20110401
A rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of olopatadine concentration in human plasma. Journal of analytical toxicology 20110301
Intrastromal corneal ring segments for bilateral keratoconus in an 11-year-old boy. Journal of cataract and refractive surgery 20110101
Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug design, development and therapy 20110101
Olopatadine hydrochloride inhibits capsaicin-induced flare response in humans. Pharmacology 20110101
Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis. Allergy and asthma proceedings 20110101
Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis. Allergy and asthma proceedings 20110101
Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis. American journal of rhinology & allergy 20110101
Olopatadine suppresses the late phase reaction in parthenium dermatitis. Indian journal of dermatology, venereology and leprology 20110101
Stability-indicating high-performance column liquid chromatography and high-performance thin-layer chromatography methods for the determination of olopatadine hydrochloride in tablet dosage form. Journal of AOAC International 20110101
Dermatitis induced by estrogen and progesterone: dual positive results on the intradermal skin test. Dermatitis : contact, atopic, occupational, drug 20110101
Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis. Current medical research and opinion 20100701
Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis. Eye & contact lens 20100701
Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert opinion on pharmacotherapy 20100601
Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert opinion on pharmacotherapy 20100401
Olopatadine nasal spray for the treatment of allergic rhinitis. Expert review of clinical immunology 20100301
Histamine stimulates interleukin-6 production through histamine H1 receptors in human amnion cells. Gynecologic and obstetric investigation 20100101
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. Allergy and asthma proceedings 20100101
Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. European journal of ophthalmology 20100101
[Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro]. [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20100101
Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy and asthma proceedings 20100101
Olopatadine hydrochloride improves dermatitis score and inhibits scratch behavior in NC/Nga mice. International archives of allergy and immunology 20100101
Synergetic effects of prednisolone and olopatadine on atopic dermatitis model of hairless mice. Pharmacology 20100101
Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study. Allergy and asthma proceedings 20100101
Antihistaminic drug olopatadine downmodulates CCL17/TARC production by keratinocytes and Langerhans cells. The Journal of dermatology 20091201
Olopatadine hydrochloride inhibits scratching behavior induced by a proteinase-activated receptor 2 agonist in mice. Journal of dermatological science 20091101
Azelastine and olopatadine in the treatment of allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20091101
Multiple action agents and the eye: do they really stabilize mast cells? Current opinion in allergy and clinical immunology 20091001
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta ophthalmologica 20090801
Cerebral histamine H1 receptor binding potential measured with PET under a test dose of olopatadine, an antihistamine, is reduced after repeated administration of olopatadine. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20090601
Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride. The Journal of dermatology 20090401
Drug approvals: '08 in review. Olopatadine hydrochloride (Patanase) nasal spray. The Nurse practitioner 20090201
Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. Journal of dermatological science 20090101
Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clinical therapeutics 20090101
Is conjunctival allergen challenge a model of seasonal rhinoconjunctivitis? Allergy and asthma proceedings 20090101
Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study. Clinical drug investigation 20090101
Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis. Allergy and asthma proceedings 20090101
Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC ophthalmology 20090101
Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit. Journal of investigational allergology & clinical immunology 20090101
Efficacy of repeated pretreatment with olopatadine hydrochloride on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats. Pharmacology 20090101
Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis. Allergy and asthma proceedings 20090101
[Effectiveness of olopatadine therapy in seasonal allergic conjunctivitis]. Oftalmologia (Bucharest, Romania : 1990) 20090101
[Comparison of olopatadin and ketotifen in the treatment of allergic conjunctivitis]. Revista medica del Instituto Mexicano del Seguro Social 20090101
Comparison of the conjunctival toxicity of topical ocular antiallergic agents. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20081201
Repeated pre-treatment with antihistamines suppresses [corrected] transcriptional up-regulations of histamine H(1) receptor and interleukin-4 genes in toluene-2,4-diisocyanate-sensitized rats. Journal of pharmacological sciences 20081201
Effects of olopatadine in limited scleroderma with peripheral eosinophils. Geriatrics & gerontology international 20080901
Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis. Archives of dermatological research 20080701
The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20080701
Effect of olopatadine hydrochloride, an anti-histamine drug, on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats. International immunopharmacology 20080601
Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis. Experimental eye research 20080501
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert opinion on drug metabolism & toxicology 20080401
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale. Methods and findings in experimental and clinical pharmacology 20080401
Progress in allergy signal research on mast cells: up-regulation of histamine signal-related gene expression in allergy model rats. Journal of pharmacological sciences 20080301
Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Current medical research and opinion 20080201
Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function. Pharmacology 20080101
The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism. Pharmacology 20080101
P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist. Drug metabolism and pharmacokinetics 20080101
Enhancement of basophil apoptosis by olopatadine and theophylline. Allergy and asthma proceedings 20080101
A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy and asthma proceedings 20080101
Comparative study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%. Allergy and asthma proceedings 20080101
Use of olopatadine ophthalmic solution and reactivity of histamine skin testing. Allergy and asthma proceedings 20080101
An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20071201
Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Current eye research 20071201
Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20071101
[Pharmacological profile and clinical efficacy of olopatadine hydrochloride ophthalmic solution (Patanol 0.1% ophthalmic solution)]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20070901
Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070801
Safety and tolerability of olopatadine 0.2% in children and adolescents. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070801
The effect of H1 antagonists carebastine and olopatadine on histamine induced expression of CC chemokines in cultured human nasal epithelial cells. Allergology international : official journal of the Japanese Society of Allergology 20070601
Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Current medical research and opinion 20070601
Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice. The British journal of dermatology 20070501
Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070201
Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines. Journal of investigational allergology & clinical immunology 20070101
Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy and asthma proceedings 20070101
Chronic red eyes. Diagnosis: allergic conjunctivitis due to airborne allergen. Comprehensive ophthalmology update 20070101
Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy and asthma proceedings 20070101
Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Advances in therapy 20070101
Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy and asthma proceedings 20070101
Olopatadine attenuates the enhancement of capsaicin-evoked substance P release by bradykinin from cultured dorsal root ganglion neurons. European journal of pharmacology 20061215
Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye & contact lens 20061201
Neuronal conditions of spinal cord in dermatitis are improved by olopatadine. European journal of pharmacology 20061010
[Clinical effects of olopatadine hydrochloride on pruritus in skin diseases]. Arerugi = [Allergy] 20061001
Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Clinical therapeutics 20061001
[The use of 'Antigrippin-maximum' in the complex therapy of patients with acute respiratory diseases]. Voenno-meditsinskii zhurnal 20061001
[First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis]. Orvosi hetilap 20060910
Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK. Current medical research and opinion 20060901
Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment. Investigative ophthalmology & visual science 20060801
[Misleading advertisement on Opatanol]. Nederlands tijdschrift voor geneeskunde 20060701
Pharmacotherapy of allergic eye disease. Expert opinion on pharmacotherapy 20060601
Red, itchy eyes, giant papillae. Advance for nurse practitioners 20060301
Role of substance P in allergic nasal symptoms in rats. European journal of pharmacology 20060217
Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis. Acta ophthalmologica Scandinavica 20060201
Histamine-induced vasodilation and vasoconstriction in the mesenteric resistance artery of the rat. European journal of pharmacology 20060104
Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. British journal of clinical pharmacology 20060101
Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators of inflammation 20060101
Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. Allergy and asthma proceedings 20060101
[Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis]. Arquivos brasileiros de oftalmologia 20060101
Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology 20051201
Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051201
The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice. European journal of pharmacology 20051107
Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051101
Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20051001
Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051001
The various effects of four H1-antagonists on serum substance P levels in patients with atopic dermatitis. The Journal of dermatology 20051001
Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Current medical research and opinion 20050901
Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clinical therapeutics 20050901
Prediction of genotoxicity of chemical compounds by statistical learning methods. Chemical research in toxicology 20050601
Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Current medical research and opinion 20050501
A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Clinical therapeutics 20050501
Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat. Ocular immunology and inflammation 20050201
[Examination of effectiveness of olopatadine hydrochloride in atopic dermatitis]. Arerugi = [Allergy] 20050201
Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20050101
Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: suppressive effects on skin response to histamine iontophoresis. The Journal of dermatology 20050101
Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. Journal of dermatological science 20041201
Effects of olopatadine hydrochloride, an antihistamine drug, on skin inflammation induced by repeated topical application of oxazolone in mice. The British journal of dermatology 20041201
Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Current medical research and opinion 20041201
A review of olopatadine for the treatment of ocular allergy. Expert opinion on pharmacotherapy 20040901
Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clinical and experimental dermatology 20040901
Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Current medical research and opinion 20040801
Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Current medical research and opinion 20040801
Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clinical therapeutics 20040801
Ocular allergy treatment comparisons: azelastine and olopatadine. Current allergy and asthma reports 20040701
A review of the use of olopatadine in allergic conjunctivitis. International ophthalmology 20040501
Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophilic leukemia (RBL-2H3) cells. Biochemical pharmacology 20040401
[Olopatadine]. Revue de l'infirmiere 20040401
The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20040101
Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy and asthma proceedings 20040101
Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittel-Forschung 20040101
Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers. Human psychopharmacology 20031201
Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocular immunology and inflammation 20031201
Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clinical therapeutics 20031001
Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta ophthalmologica Scandinavica 20030801
Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clinical therapeutics 20030801
[Opatanol]. Ugeskrift for laeger 20030721
One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears. Clinical therapeutics 20030701
Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells. Cellular immunology 20030701
Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model. Eye & contact lens 20030401
[In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter]. Journal francais d'ophtalmologie 20030401
Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. International archives of allergy and immunology 20030301
A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clinical therapeutics 20030301
Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort. Advances in therapy 20030101
Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug metabolism and disposition: the biological fate of chemicals 20021201
A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clinical therapeutics 20021001
Compared topical ocular olopatadine 0.1% (Patanol) and loteprednol etabonate 0.2% (Alrex) in an allergen challenge model. Clinical therapeutics 20020901
Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study. Clinical therapeutics 20020801
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clinical therapeutics 20020701
Occupational allergy caused by Peruvian lily (Alstroemeria). Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20020601
Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clinical therapeutics 20020601
Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20020501
Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochemical and biophysical research communications 20020412
Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Japanese journal of pharmacology 20020401
Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils. Japanese journal of pharmacology 20020401
Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine. Allergy and asthma proceedings 20020101
Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20011101
Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and the scratching behavior induced by poly-L-arginine in rats. Japanese journal of pharmacology 20011001
Mucus fishing syndrome: case report and new treatment option. Optometry (St. Louis, Mo.) 20011001
Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clinical therapeutics 20010801
[Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010701
Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20010601
[Effect of olopatadine hydrochloride, a novel antiallergic agent, on the QT interval in dogs]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010601
Inhibitory effect of olopatadine hydrochloride on the sneezing response induced by intranasal capsaicin challenge in guinea pigs. Japanese journal of pharmacology 20010601
Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs. Japanese journal of pharmacology 20010401
Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 19971201
The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 19960101

Related Products

© 2019 Angene International Limited. All rights Reserved.